Cantor Fitzgerald Maintains Overweight on Artiva Biotherapeutics, Raises Price Target to $40

Cantor Fitzgerald analyst Josh Schimmer maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and raises the price target from $10 to $40.